From Fermentation Platform to Commercial Product: Building the Industrial Biotech Story

Industrial biotech commercialisation is the move from a biological production system that works to a product customers can qualify, buy and receive at a scale and cost that work for them. The commercial story should follow the same path. Start with the market shift and the buyer's constraint, make the product concrete, and then use the fermentation platform to explain why the company can deliver a result others cannot.

What changed for the buyer?

A product becomes relevant when something in the buyer's world moves. The shift might be fossil input volatility, a new regulation, concentrated supply, customer demand for lower-carbon inputs, a new performance requirement or better biological production economics. Pick the one that actually changes the buyer's decision this year. Opening with "biology is the future" tells the buyer about your worldview and nothing about their problem.

Then describe the constraint in operational terms. A materials company may need a lower-carbon input that still meets its specification. A feed producer may need protein supply that holds up when a commodity market swings. A chemicals company may want a bio-based route that fits its existing process. Written this way, the buyer recognises the problem before the technology appears. For readers who need the field explained first, our primer on what industrial biotechnology is covers the basics.

What exactly is the product?

Name the output. State the form it takes, the specification that matters, where it is used and what the customer physically receives. This sounds basic, and platform companies still make the product harder to find than the production method. A reader who finishes your homepage able to describe your bioreactor and unable to name your product has been given the wrong story.

The product then has to compete with something. Show the dimensions the buyer will judge it on, which may include purity, functionality, consistency, price, cost in use, handling, storage, regulatory status and supply. Choose the three that decide the sale for this buyer and lead with them. A long table of laboratory metrics is useful in a technical pack and slows down everyone else.

Why does the biology create an advantage?

Now bring in the platform. Explain what about the organism, the feedstock, the fermentation, the enzymes, the downstream processing or the wider biorefinery makes the product possible or better. The mechanism has one job at this point, which is to support the buyer-facing claim. Every technical paragraph should end in a consequence the buyer can use.

Economics belong here too. Researchers use titre, rate and yield, often shortened to TRY, to evaluate production costs in microbial biotechnology. Those three numbers connect the biology to the price. If your platform improves one of them, say which one, by how much against which baseline, and what that does to cost in use for the customer.

What has run, and at what scale?

Industrial biotech needs maturity labels. Distinguish a lab result from bench scale, pilot, demonstration, toll manufacturing, a first commercial plant and existing commercial supply. The exact stages vary by process. The reader should never have to guess whether a product is available now or expected later.

The bio-BDO story shows the path in public. Genomatica developed its GENO BDO process to make butanediol, a major intermediate chemical, by fermentation. In 2016 Novamont opened what it described as the world's first commercial plant for bio-production of a major intermediate chemical, and Novamont's own release called it the first industrial-scale plant producing butanediol via fermentation of renewable raw materials. In 2017 Genomatica announced that it had delivered on plant performance guarantees.

Look at the order of that public record. The product was a named chemical with an existing market. The plant was a named site run by a named operator. The evidence that followed was a performance guarantee, the kind of statement a plant owner, a lender and a customer can all use. The platform was present throughout, and it did its work as proof.

How will supply scale?

A buyer may test a sample with enthusiasm and still refuse a long qualification process without confidence in supply. Explain the current production route, the manufacturing partner or facility, the capacity, the quality system, the feedstock, the planned scale-up and the major dependencies. Label future capacity as future, with the date and the condition it depends on. If the first commercial volumes will come from a contract manufacturer, say so, and say what happens to supply if that partner's schedule slips. Buyers qualify suppliers as well as products, and a clear account of the manufacturing route is often what moves a trial into a purchase order.

Evidence should match the decision in front of each reader. A formulation team needs sample performance. Procurement needs economics and supply terms. A strategic partner may need integration data. An investor may need plant design, customer commitments and a view of what the first plant proves, which is where the story meets FOAK thinking for biomanufacturing. Build the evidence architecture around those decisions.

One fact base, several cuts

Most industrial biotech companies need four pieces of material drawn from the same source of truth.

• A buyer brief covering product, application, proof and supply.
• A technical pack covering mechanism, specification and validation data.
• An investor deck covering market shift, wedge, platform, economics and scale.
• A plant or FOAK case covering project, risk, offtake, capital and repeatability.

One source of truth, different cuts. Keep the numbers identical across all four. A yield figure that differs between the deck and the technical pack will be found in diligence, and it will cost more time than it took to fix. The product-first logic behind the buyer brief is set out in industrial biotech positioning.

Show what transfers to product two

The platform earns its strategic role through repeatability. A claim that the company can make many things is easy to write and hard to assess. A claim that the capabilities built for product one give a measurable head start on product two is something an investor can test. Show what transfers, whether that is strain engineering, fermentation know-how, a downstream process, a feedstock network, regulatory learning, manufacturing infrastructure or customer channels.

As the company scales, the language of the story should move from possibility to obligation. Specification, volume, delivery, quality, cost, contracts and plant performance take over from vision. The ambition stays the same size and becomes industrial. Public funders see the same gap. The Circular Bio-based Europe Joint Undertaking funds demonstration plants and first-of-their-kind biorefineries because a commercial gap sits between technical promise and industrial operation. To start, write the one sentence that names your product, its buyer and the constraint it removes, and check that every page of your deck supports it. If the sentence will not hold, our pitch and investor narrative work begins there, and the wider set of articles sits in the food tech, biotech and biomanufacturing library.

Sources and further reading

• TRYing to evaluate production costs in microbial biotechnology, Trends in Biotechnology, 2024
• Novamont opens world's first commercial plant for bio-production of a major intermediate chemical, GlobeNewswire, 2016
• Genomatica delivers on plant performance guarantees, GlobeNewswire, 2017
• Circular Bio-based Europe Joint Undertaking, programmes and projects, 2026